-
Views
-
Cite
Cite
Roger L. Nation, Tony Velkov, Jian Li, Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?, Clinical Infectious Diseases, Volume 59, Issue 1, 1 July 2014, Pages 88–94, https://doi.org/10.1093/cid/ciu213
Close - Share Icon Share
Abstract
Colistin and polymyxin B have indistinguishable microbiological activity in vitro, but they differ in the form administered parenterally to patients. Polymyxin B is administered directly as the active antibiotic, whereas colistin is administered as the inactive prodrug, colistin methanesulfonate (CMS). CMS must be converted to colistin in vivo, but this occurs slowly and incompletely. Here we summarize the key differences between parenteral CMS/colistin and polymyxin B, and highlight the clinical implications. We put forth the view that overall polymyxin B has superior clinical pharmacological properties compared with CMS/colistin. We propose that in countries such as the United States where parenteral products of both colistin and polymyxin B are available, prospective studies should be conducted to formally examine their relative efficacy and safety in various types of infections and patients. In the meantime, where clinicians have access to both polymyxins, they should carefully consider the relative merits of each in a given circumstance.
